Indivior PLC JP Morgan Healthcare Conference (5861T)
10 January 2017 - 12:00AM
UK Regulatory
TIDMINDV
RNS Number : 5861T
Indivior PLC
09 January 2017
Indivior PLC (the 'Company')
Shaun Thaxter, CEO of Indivior PLC is presenting at the JP
Morgan Healthcare Conference on January 11(th) , 2017 at 4pm
Pacific time (12am UK time). A link to the webcast of the
presentation is provided and the slides can be downloaded in pdf
format on the Company's website at www.indivior.com. In addition, a
playback of the presentation will be available for 3 months.
About Indivior
Indivior is a global specialty pharmaceutical company with a
20-year legacy of leadership in patient advocacy, health policy and
evidence-based best practice models that have revolutionized modern
addiction treatment. Indivior is dedicated to transforming
addiction from a global human crisis to a recognized and treated
chronic disease. Building on its robust, global opioid dependence
portfolio, Indivior has a strong pipeline of product candidates
designed to both expand treatments in opioid dependence and address
other chronic diseases of addiction - including alcohol use
disorder, cocaine intoxication and schizophrenia. Headquartered in
the United States in Richmond, VA, Indivior employs more than 900
individuals globally and its portfolio is available in over 40
countries worldwide. Its name is a fusion of the words individual
and endeavor and its logo radiates the company's patient-centered
holistic focus on expanding access to high-quality treatment
services for addiction worldwide. For additional product
information, please visit www.indivior.com
Investor Enquiries
Tom Corran, IR Director, Indivior PLC
+44 1753 423965
tom.corran@indivior.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSAFMMFWSESF
(END) Dow Jones Newswires
January 09, 2017 08:00 ET (13:00 GMT)
Indivior (LSE:INDV)
Historical Stock Chart
From Apr 2024 to May 2024
Indivior (LSE:INDV)
Historical Stock Chart
From May 2023 to May 2024